Investor Information


NEWS

October 21, 2018

CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY

CEL-SCI REPORTS RECENT DATA REVIEW BY THE INDEPENDENT DATA MONITORING COMMITTEE FOR ITS PIVOTAL PHASE 3 HEAD AND NECK CANCER STUDY Vienna, VA, August 15, 2018 — […]
October 21, 2018

CEL-SCI ANNOUNCES THAT THE NYSE AMERICAN APPROVES PLAN

CEL-SCI ANNOUNCES THAT THE NYSE AMERICAN APPROVES PLAN Vienna, VA, August 17, 2018 — CEL-SCI Corporation (NYSE American: CVM)announces that the NYSE American (the “Exchange”) has accepted the […]
October 21, 2018

CEL-SCI CORPORATION RELEASES LETTER TO SHAREHOLDERS

Vienna, VA, August 21, 2018 — The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual meeting: Dear CEL-SCI […]

Corporate Overview


CEL-SCI Corporation (NYSE MKT: CVM), a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances.

If you would like to share your feedback with us via e-mail, we invite you to send us your comments or letters to Feedback@cel-sci.com.

CORPORATE HEADQUARTERS

CEL-SCI Corporation
8229 Boone Boulevard, Suite 802
Vienna, VA 22182 USA
Telephone (703) 506-9460
Facsimile (703) 506-9471

STOCK PROFILE

CEL-SCI Corporation's Common Stock is traded on the NYSE MKT Exchange under the symbol CVM. CEL-SCI also trades on the German Stock Exchanges under the symbol LSR, German Securities Code (Wertpapierkennnummer) 871006. There are approximately 1,000 stockholders of record as of September 30, 2016. The Company has not paid cash dividends on its Common Stock since its inception.

CVM Stock

Stock Rising

CORPORATE OFFICERS

STOCKHOLDERS INQUIRIES

Inquiries regarding transfer requirements, lost certificates and change of address should be directed to the transfer agent.


BOARD OF DIRECTORS

1
Geert R. Kersten
Chief Executive Officer
CEL-SCI Corporation

2
Robert Watson*
President
Preparedness Technology
Division at Intermedix

3
Peter Young, Ph.D.**
Chief Executive Officer
Agnus Dei, LLC.

4
Bruno Baillavoine**
Executive Chairman
Globomass Holdings Limited


* Independent director
* Independent directors and members of the Compensation, Nominating and Audit Committees.
Dr. Young serves as the audit committee's financial expert and chairman of the Compensation, Nominating and Audit Committees.
Audit Committee Charter
Nominating Committee Charter
Compensation Committee Charter
CVM 7,04 -0,20 -2,81% 

Holders of CEL-SCI's common stock can send written communications to CEL-SCI's entire Board of Directors, or to one or more Board members, by addressing the communication to "the Board of Directors" or to one or more directors, specifying the director or directors by name, and sending the communication to CEL-SCI's offices in Vienna, Virginia. Communications addressed to the Board of Directors as whole will be delivered to each Board member. Communications addressed to a specific director (or directors) will be delivered to the director (or directors) specified.


SEC FORM 10-K


A copy of the Company's annual report to the Securities and Exchange Commission on Form 10-K is available without charge upon written request to:

Corporate Communications CEL-SCI Corporation
8229 Boone Boulevard, Suite 802
Vienna, VA 22182 USA